Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...

MyRisk is expected to continue its strong ... and we've been pretty open about those things. The strength of Myriad Genetics, though, is the diversity of our portfolio and the many different ...

Myriad Genetics, Inc. MYGN recently made SneakPeek available over the counter in more than 8,800 retail locations nationwide.

that allows physicians to order Myriad Genetics’ MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform ...

In October 2024, Myriad Genetics entered a collaboration with Flatiron Health, a leading health technology company, that allows physicians to order Myriad Genetics' MyRisk Hereditary Cancer Test and ...

In October 2024, Myriad Genetics entered a collaboration with Flatiron Health, a leading health technology company, that allows physicians to order Myriad Genetics’ MyRisk Hereditary ...

SALT LAKE CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ...

TD Cowen lowered the firm’s price target on Myriad Genetics (MYGN) to $20 from $30 and keeps a Hold rating on the shares. The firm said a focal point tonight was assessing UnitedHealth’s (UNH ...

Myriad Genetics generated approximately $10 million and $40 million of GeneSight revenue from UNH's commercial population in the third quarter and trailing twelve month period ended September 30, ...